Advanced

Benefit of Treating Hepatocellular Carcinoma Recurrence after Liver Transplantation and Analysis of Prognostic Factors for Survival in a Large Euro-American Series

Sapisochin, G.; Goldaracena, N.; Astete, S.; Laurence, J. M.; Davidson, D.; Rafael, Ehab LU ; Castells, L.; Sandroussi, C.; Bilbao, I. and Dopazo, C., et al. (2015) In Annals of Surgical Oncology 22(7). p.2286-2294
Abstract
To identify prognostic factors after hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT). We retrospectively reviewed the combined experience at Toronto General Hospital and Hospital Vall d'Hebron managing HCC recurrence after LT (n = 121) between 2000 and 2012. We analyzed prognostic factors by uni- and multi-variate analysis. Median follow-up from LT was 29.5 (range 2-129.4) months. Median follow-up from HCC recurrence was 12.2 (range 0.1-112.5) months. At recurrence, 31.4 % were treated with curative-intent treatments (surgery or ablation), 42.1 % received palliative treatment, and 26.4 % received best supportive care. The 1-, 3-, and 5-year survivals, respectively, after HCC recurrence were 75, 60, and 31 %, vs.... (More)
To identify prognostic factors after hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT). We retrospectively reviewed the combined experience at Toronto General Hospital and Hospital Vall d'Hebron managing HCC recurrence after LT (n = 121) between 2000 and 2012. We analyzed prognostic factors by uni- and multi-variate analysis. Median follow-up from LT was 29.5 (range 2-129.4) months. Median follow-up from HCC recurrence was 12.2 (range 0.1-112.5) months. At recurrence, 31.4 % were treated with curative-intent treatments (surgery or ablation), 42.1 % received palliative treatment, and 26.4 % received best supportive care. The 1-, 3-, and 5-year survivals, respectively, after HCC recurrence were 75, 60, and 31 %, vs. 60, 19, and 12 %, vs. 52, 4, and 5 % (p < 0.001). By multivariate analysis, not being amenable to a curative-intent treatment [hazard ratio (HR) 4.7, 95 % confidence interval (CI) 2.7-8.3, p < 0.001], alpha-fetoprotein of a parts per thousand yen100 ng/mL at the time of HCC recurrence (HR 2.1, 95 % CI 1.3-2.3, p = 0.002) and early recurrence (< 12 months) after LT (HR 1.6, 95 % CI 1.1-2.5, p = 0.03) were found to be poor prognosis factors. A prognostic score was devised on the basis of these three independent variables. Patients were divided into three groups, as follows: good prognosis, 0 points (n = 22); moderate prognosis, 1 or 2 points (n = 84); and poor prognosis, 3 points (n = 15). The 1-, 3-, and 5-year actuarial survival for each group was 91, 50, and 50 %, vs. 52, 7, and 2 %, vs. 13, 0, and 0 %, respectively (p < 0.001). Patients with HCC recurrence after transplant amenable to curative-intent treatments can experience significant long-term survival (similar to 50 % at 5 years), so aggressive management should be offered. Poor prognosis factors after recurrence are not being amenable to a curative-intent treatment, alpha-fetoprotein of a parts per thousand yen100 ng/mL, and early (< 1 year) recurrence after LT. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Annals of Surgical Oncology
volume
22
issue
7
pages
2286 - 2294
publisher
Springer
external identifiers
  • wos:000355748300025
  • scopus:84930483026
ISSN
1534-4681
DOI
10.1245/s10434-014-4273-6
language
English
LU publication?
yes
id
5411279e-5c05-4daf-acaa-2d3bbf1751e4 (old id 7602039)
date added to LUP
2015-08-03 10:10:36
date last changed
2017-10-01 04:24:40
@article{5411279e-5c05-4daf-acaa-2d3bbf1751e4,
  abstract     = {To identify prognostic factors after hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT). We retrospectively reviewed the combined experience at Toronto General Hospital and Hospital Vall d'Hebron managing HCC recurrence after LT (n = 121) between 2000 and 2012. We analyzed prognostic factors by uni- and multi-variate analysis. Median follow-up from LT was 29.5 (range 2-129.4) months. Median follow-up from HCC recurrence was 12.2 (range 0.1-112.5) months. At recurrence, 31.4 % were treated with curative-intent treatments (surgery or ablation), 42.1 % received palliative treatment, and 26.4 % received best supportive care. The 1-, 3-, and 5-year survivals, respectively, after HCC recurrence were 75, 60, and 31 %, vs. 60, 19, and 12 %, vs. 52, 4, and 5 % (p &lt; 0.001). By multivariate analysis, not being amenable to a curative-intent treatment [hazard ratio (HR) 4.7, 95 % confidence interval (CI) 2.7-8.3, p &lt; 0.001], alpha-fetoprotein of a parts per thousand yen100 ng/mL at the time of HCC recurrence (HR 2.1, 95 % CI 1.3-2.3, p = 0.002) and early recurrence (&lt; 12 months) after LT (HR 1.6, 95 % CI 1.1-2.5, p = 0.03) were found to be poor prognosis factors. A prognostic score was devised on the basis of these three independent variables. Patients were divided into three groups, as follows: good prognosis, 0 points (n = 22); moderate prognosis, 1 or 2 points (n = 84); and poor prognosis, 3 points (n = 15). The 1-, 3-, and 5-year actuarial survival for each group was 91, 50, and 50 %, vs. 52, 7, and 2 %, vs. 13, 0, and 0 %, respectively (p &lt; 0.001). Patients with HCC recurrence after transplant amenable to curative-intent treatments can experience significant long-term survival (similar to 50 % at 5 years), so aggressive management should be offered. Poor prognosis factors after recurrence are not being amenable to a curative-intent treatment, alpha-fetoprotein of a parts per thousand yen100 ng/mL, and early (&lt; 1 year) recurrence after LT.},
  author       = {Sapisochin, G. and Goldaracena, N. and Astete, S. and Laurence, J. M. and Davidson, D. and Rafael, Ehab and Castells, L. and Sandroussi, C. and Bilbao, I. and Dopazo, C. and Grant, D. R. and Lazaro, J. L. and Caralt, M. and Ghanekar, A. and McGilvray, I. D. and Lilly, L. and Cattral, M. S. and Selzner, M. and Charco, R. and Greig, P. D.},
  issn         = {1534-4681},
  language     = {eng},
  number       = {7},
  pages        = {2286--2294},
  publisher    = {Springer},
  series       = {Annals of Surgical Oncology},
  title        = {Benefit of Treating Hepatocellular Carcinoma Recurrence after Liver Transplantation and Analysis of Prognostic Factors for Survival in a Large Euro-American Series},
  url          = {http://dx.doi.org/10.1245/s10434-014-4273-6},
  volume       = {22},
  year         = {2015},
}